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The paradigm shift in adult oncology drug development has not been translated into drug 
development for children with cancer.  Early phase clinical trial designs for molecularly targeted 
agents and immunotherapeutics in paediatric malignancies need to be adapted to this landscape.  
This article describes the strategy of the Innovative Therapies for Children with Cancer Consortium 
for conducting early phase trials with these new agents.  
 
Therapeutic need, tumour biology and a drug’s mechanism of action (MoA) drive prioritisation of 
drug development.  Early phase paediatric trials should be biologically driven and molecular profiling 
is very strongly encouraged.  Uninterrupted recruitment and extrapolation from adult studies when 
possible is ideal.  If a drug has neither serious, dose-related toxicities nor a narrow therapeutic index 
then studies should generally start at the adult recommended phase II dose corrected for body 
surface area and act as dose confirmation studies.  These trials should encompass expansion cohorts 
providing further data on toxicity, pharmacokinetics, pharmacodynamics and importantly activity.  
With adaptive trial designs, promising drugs can rapidly progress to randomised studies.  
Pharmacology in young children and developmental toxicities can be addressed in subsequent 
studies.  This model, together with MoA drug development, will substantially accelerate drug 
development for children and adolescents with cancer.  
 
  





Introducing novel drugs, molecularly targeted agents and immunotherapeutics, into front-line 
treatment for paediatric malignancies is essential to improve outcomes for children and adolescents 
with cancer.  There is a major unmet need for new therapies as thousands of children with cancer 
still die from their disease1 and for a significant proportion of survivors long-term sequelae from 
current treatments are significant2.  New drugs need to be efficiently and rapidly evaluated and the 
appropriate dose, schedule, toxicity profile, pharmacological properties and efficacy determined.  
Progress will be fragmented and slow unless there is an agreed process for this assessment.  Novel 
anti-cancer drugs comprise different agents including small tyrosine kinase inhibitors, drugs 
focussing on epigenetic alterations, immune checkpoint inhibitors and monoclonal antibodies3.  The 
goal is to achieve a comprehensive therapeutic approach integrating drugs against cancer 
vulnerabilities with inhibitors against genomic drivers, immune responses or epigenetic alterations4. 
 
In 1998 a consensus paper on the conduct of phase I studies for children with cancer was published 
by international investigators in paediatric oncology drug development5.  This manuscript reported 
the methodology for the paediatric evaluation of cytotoxic agents in common usage at that time and 
these principles are now utilised in early clinical trials for paediatric cancer.  However, in the 
experience of the Innovative Therapies for Children with Cancer (ITCC) Consortium of 51 Paediatric 
Oncology centres in 12 European countries and Israel6, the methodology described in 1998 is not 
applicable in the modern era of targeted therapies and immunotherapeutics.  Its use results in 
significant delays in the evaluation of new anti-cancer drugs in children and increased risk of giving a 
non-active dose, without serving the methodology’s purpose of reducing the risks associated with 
early clinical trials.  It is therefore time to consider a new consensus on the conduct of early clinical 
trials of targeted drugs for children with cancer. 
 
The complexities of drug development for adult cancers have significantly increased with the large 
number of meaningful molecular subtypes of most tumours and the advent of combination 
therapies, companion diagnostics and immunotherapeutics.  Nevertheless, the number of 
molecularly targeted agents being evaluated each year has grown exponentially7.  As of July 2016, 
more than 70 molecularly targeted agents have been approved by the Food and Drug Agency (FDA) 
and European Medicines Agency (EMA) for adult cancers, but to date only imatinib for chronic 
myeloid leukaemia (CML), everolimus for subependymal giant cell astrocytoma and dinutuximab for 
neuroblastoma have been approved for childhood cancers8,9.  Furthermore, despite the change in 
landscape of adult oncology with "precision medicine", there is a paucity of new drugs being 




integrated into paediatric phase III trials, and molecularly targeted agents have not been introduced 
into front-line therapy for many poor prognosis paediatric malignancies.  
 
However, new drugs directed against specific cancer targets are increasingly available for paediatric 
use, for example, inhibitors of BCR-ABL, anaplastic lymphoma kinase (ALK) and BRAF and bispecific 
T-cell engager (BiTE).  It is essential that the design of first-in-child trials is adapted to facilitate these 
new agents being more efficiently evaluated while maintaining safety.  Alternative approaches are 
needed to those required with cytotoxic drugs with treatment needing to be matched to the 
molecular characteristics of the tumour.  Molecularly targeted agents have different toxicity profiles 
to cytotoxics, with non-haematological toxicity being predominant; their efficacy generally does not 
increase with dose and their therapeutic index is wider.  In addition, it is important that all eligible 
patients who wish to receive these new drugs are offered the opportunity to participate in clinical 
trials, giving children and adolescents with relapsed disease more therapeutic options. 
 
Major changes have occurred in relation to paediatric early phase clinical trials and there is a new 
environment for cancer drug development in children.  Globally all stakeholders (academia, the 
pharmaceutical industry, parents, patient advocates, regulatory agencies, public health agencies, 
research-funding agencies and philanthropic organisations) are working closely together10,11.  On 
both sides of the Atlantic, new regulations, which aim to encourage the interest of industry in 
paediatric studies, have been implemented, including the European Paediatric Medicine Regulation 
EC No. 1901/2006 and, in the US, the Best Pharmaceuticals for Children Act (BPCA), the Paediatric 
Research Equity Act (PREA), and the Creating Hope Act12-15. 
 
Current process for evaluation of new anti-cancer drugs in children 
As paediatric drug development is still largely centred on adult conditions, with the exception of 
anti-GD2 targeted therapies for neuroblastoma16, the majority of drugs that reach paediatric clinical 
development have already been extensively explored in adult trials.  Despite the regulatory and 
scientific motivation to commence first-in-child studies at completion of first-in-man trials, in reality, 
paediatric phase I trials generally start after pivotal phase III studies are near completion in adults, 
thereby delaying children’s access to these new drugs substantially. 
 
Traditional practice has been that all drugs evaluated in children have to go through a dose 
escalation phase, using methods such as 3+317 or the rolling six18, with multiple dose levels until a 
maximum tolerated dose (MTD) and recommended phase II dose (RP2D) are identified.  The starting 




dose for this dose escalation has conventionally been 80% of the adult RP2D5.  Classic dose 
escalation designs were developed for cytotoxic drugs where the main toxicities are dose-related 
(i.e., haematological toxicities), and their main objective was to prevent and limit severe toxicities by 
only allowing small groups of patients to receive increasing doses of the agent(s).  This approach, 
although successful with some drugs, sometimes has resulted in long phase I trials, with many dose 
levels, multiple episodes of suspended recruitment whilst patients waited for assessment for dose 
limiting toxicity (DLT) evaluation, and the requirement for large numbers of patients (Table1).  
Hence, for targeted drugs the use of this classic dose escalation model based on the identification of 
DLTs and definition of an MTD has slowed progress while not resulting in an enhanced protection 
against undesirable side effects. 
 
Following on from phase I studies, the tradition has been to evaluate activity in single arm phase II 
studies and then in different relapsed strategies before reaching front-line trials.   
 
Disadvantages of the current process for evaluation of new anti-cancer drugs in children 
In addition to drug development being largely driven by the availability of drugs developed or 
marketed for adults, rather than mechanism of action (MoA)20, the current process for evaluation of 
new anti-cancer drugs is not suitable for paediatric studies of molecularly targeted agents and 
immunotherapeutics for two main reasons.  First, for molecularly targeted drugs, most toxicities are 
not necessarily dose-related but class-related.  Tolerable paediatric doses will likely be equivalent to 
the adult ones corrected for body surface area (BSA), which results in the same pharmacokinetic 
values of area under the concentration time curve and trough levels as the adult doses.  In a 
published analysis of the paediatric MTD for all 25 molecularly targeted agents approved by the FDA 
or EMA up to 2012, we demonstrated that for 75% of molecularly targeted agents, the established 
paediatric RP2D was between 90% and 130% of the BSA-adjusted approved dose in adults.  
Significantly, this report also showed that for molecularly targeted agents, toxicities seen in 
paediatric studies were those seen in adults and main pharmacokinetic parameters in children were 
comparable with those observed in adults21,22. The only drug in the 25 where DLT was observed in 
children at lower dose levels than in adults was sunitinib.  The main toxicities differed too, despite 
similar pharmacokinetic parameters, myelosuppression and transaminase elevations were the most 
commonly reported toxicities in children compared to fatigue and gastrointestinal symptoms in 
adults.  The mechanism for this is uncertain, however, children have tolerated higher doses and a 
large percentage of adults on sunitinib undergo dose reductions with cumulative dosing.  
Furthermore, the choice of paediatric population – heavily pre-treated children with relapsed/ 




refractory solid tumours – might have contributed to this finding23,24.  Thus paediatric dosing can 
begin at the adult RP2D (adjusted for BSA) for some targeted agents for which the adult RP2D is not 
based on toxicity and is below the MTD. 
 
A further consideration is that molecularly targeted agents are evaluated in the paediatric 
population at doses below those already established to be active in adults, raising ethical concerns, 
as therapeutic intent is central to studies in children25.  The paediatric starting dose for most agents 
should be an equivalent dose of the minimum active target exposure. 
 
Amongst the challenging areas in paediatric drug development are pharmacological differences and 
developmental toxicities in children less than three years of age26.  The small number of infants and 
young children participating in early clinical trials poses practical difficulties in addressing 
pharmacokinetic differences at each dose level, or even during the whole dose escalation trial.  In a 
recent report from eight large ITCC centres, only 9 of 270 (3.3%) patients participating in dose 
determining trials were below 3 years of age27.  Moreover, evaluation of developmental toxicities 
requires longer survival and follow up, so these would generally be studied in late stage or upfront 
trials, although for some very active agents, data on developmental toxicities should also be 
collected in early phase trials28.  
 
In summary, trial designs that require systematic dose escalations are not efficient for paediatric 
development for molecularly targeted drugs and immunotherapeutics.  They add unnecessary time 
to the duration of studies and require some patients to be treated at doses lower than the adult 
MTD/RP2D, while at the same time not protecting paediatric patients from unacceptable, 
unexpected or paediatric-specific toxicities.  
 
Objectives of first-in-child studies 
The main aim of first-in-child studies is to determine the toxicity profile and the RP2D and schedule 
for further evaluation of a new drug.  The RP2D may also take into account available data about the 
toxicity profile measured at all treatment cycles (and not only at the first treatment cycle), 
pharmacokinetics, pharmacodynamic (target inhibition) biomarkers and preliminary data about 
activity.  For a number of drugs the MTD is not required as a biological effect can be obtained with 
doses below the MTD where biological effect has guided the paediatric RP2D. With targeted drugs it 
is not necessary to escalate the dose to an MTD, but rather a RP2D can be based on an integration of 




available adult, toxicity, activity and biomarker data.  Much of this information can be extrapolated 
from adult studies29 and will be obtained in later phases of the development of the drug.  
 
Initial dose for first-in-child early clinical trials 
As mentioned, a publication analysing 19 paediatric dose finding trials of molecular targeted agents 
found that the paediatric RP2D of molecularly targeted agents ranged between 90% and 130% of the 
BSA adjusted approved dose in adults for most drugs, and often based on pharmacokinetic and 
pharmacodynamic end points in the absence of DLT21.  This, taken together with the fact that the 
short-term safety profiles and DLT described in paediatric phase I trials are similar to those reported 
in the adult population, means that identifying toxicity that has not been documented in adults 
previously is very rare.  Furthermore, 25% of paediatric dose finding trials of molecularly targeted 
drugs never identify an MTD due to absence of DLT. 
 
If the toxicity profile and the pharmacokinetic parameters observed in children treated at the adult 
RP2D are similar to those in adults, escalating to the MTD is not necessarily required, unless a dose-
activity relationship has been documented in adults.  Therefore, we recommend that where possible 
paediatric first-in-child studies of molecularly targeted agents should start at 100% of the BSA 
adjusted equivalent approved RP2D for exposure in adults (Figure 1).  There are specific situations 
where the benefit/risk ratio should be weighed against this recommendation.  In cases of specific, 
serious, dose-related toxicities or a narrow therapeutic index, dose escalation should start at 80% of 
the adult RP2D and escalate to 100% and 120% if indicated (Figure 1).  In this context we define 
therapeutic index as the ratio of the highest exposure to the drug that results in no toxicity to the 
exposure that produces the desired efficacy30.  This recommendation is supported by the ITCC 
experience since 2003 across 25 dose finding trials, together with a systematic review of paediatric 
dose finding studies conducted for all molecularly targeted drugs approved for adult cancer 
indications up to 201221.  This experience shows that for molecularly targeted drugs, starting at 
lower doses is not useful in preventing severe toxicities.  
 
The proposed approach aims to maximise the information from adult studies and extrapolate from 
existing data where possible, as supported recently by the EMA29.  This extrapolation is very feasible 
for studies of molecularly targeted drugs for conditions that occur both in adults and children (such 
as CML) and when there are shared common molecular aberrations (such as BRAF mutated cancers 
– melanoma and high grade glioma31).  Therefore for many drugs with a wide therapeutic index, only 
a dose confirmation study will be required with a limited sample size.  For instance, analysis of ten 




patients would generally limit the risk of missing adverse events with a 33% (or more) prevalence, 
corresponding to a futility analysis for a 30% activity rate target or more and allow for estimation of 
key pharmacokinetic parameters, providing that the pharmacokinetic population model is known 
from adults32; and if the safety profile and pharmacokinetics are equivalent to those in adults, the 
paediatric RP2D can be determined (Figure 1).  Escalating up to the MTD in children if this dose is 
higher than the RP2D is then not necessary.  Small studies can provide sufficient information to 
proceed to later stages of development to define activity/efficacy, as exemplified by recent studies 
with nilotinib33.  
 
Most monoclonal antibodies do not generally require a dose escalation study, for example, 
brentuximab for CD30+ lymphomas34, 35 and antibodies against insulin-like growth factor receptor 1 
36-40, which only required small dose confirmation studies.  In general, if the adult RP2D is not based 
on toxicity and is below the adult MTD, then paediatric dosing can begin at the adult RP2D adjusted 
for BSA regardless of agent class. 
 
In the absence of particular safety issues, designs that remain closed for a significant part of the time 
should not be employed, since they pose an additional burden for patients and parents waiting for 
trial allocations.  Uninterrupted recruitment is a priority as soon as deemed safe (e.g., after the first 
dose level or cohort of patients is analysed). 
 
If a drug has specific, serious, dose-related toxicities or a narrow therapeutic index, such as 
blinatumomab (with a high tumour burden), moxetumomab or EGFR inhibitors41-43, then dose 
escalation starting from 80% of the adult RP2D is recommended.  New dose escalation designs such 
as the Bayesian logistic regression model (BLRM) or continuous reassessment method (CRM) will 
maximise the efficiency of the dose escalation.  CRM extensions have the advantage of incorporating 
events after cycle 1, if needed, and of providing a useful tool to monitor the risk of toxicity during 
the expansion cohort.  Several studies, using simulations, have shown the superiority of model-
based designs over the 3+3 or the rolling six in the context of paediatric trials44-46.  A review of 84 
first-in-man, adult phase I trials of single targeted agents found that the number of trials with a 
median number of dose levels using CRM was almost double the number of trials using the 3+3 
method, even though the median number of patients was similar and the number of patients 
treated at higher doses than the MTD was lower with the CRM than with the 3+3 or the accelerated 
titration design.  To date there have been no such comparisons in paediatric oncology as this is 
difficult when the choice of method is not independent of the type of agent and the anticipated 




number of levels that will be escalated.  However, the rolling six would be acceptable if a limited 
number of dose levels were to be explored and accrual were not too fast; but in this situation, more 
than 6 patients at the RP2D would be required to evaluate pharmacokinetics.  Table 2 provides an 
overview of different dose escalation methods that could be used for molecularly targeted drugs and 
Table 3 illustrates recommendations for early phase studies in children based on findings from 
studies in adults.  
 
Early phase studies should include expansion cohorts 
In a homogeneous cohort of patients, expansion cohorts provide additional pharmacokinetic, 
pharmacodynamic and safety data that are more similar to the phase II setting and can identify early 
signals of anti-tumour activity44.  These cohorts aim to enrich the patient population for those 
tumours (or genomic aberrations) with a maximal probability of response based on molecular 
characteristics31 or to detect first signals in diseases of interest.  The size of expansion cohorts can be 
based on feasibility with statistical calculations that can inform go/no-go decisions45.  While not 
definitive, in the context of biomarker-rich trials they can provide very good evidence to support 
further development of a particular drug.  A smaller sample size can be sufficient to validate 
pharmacokinetic estimates when the population model is known from adults.  For drugs with a large 
therapeutic index, dose confirmation in selected patient populations with given histologies or 
molecular profiles will allow these patients to be assessed for activity. 
 
It is necessary to define in the study protocols the go/no-go decision rules in the expansion cohorts, 
particularly if the decision also incorporates signals of activity.  Once the RP2D has been determined, 
expansion cohorts are established in the disease or molecular subtypes in which there is a biological 
rationale for the drug’s MoA or an indication of activity in the dose confirmation/escalation phase.  A 
design with go/no go decision rules based on activity can be applied to the expansion cohort.  For 
instance, we implemented an Ensign 3-stage design45 in the multiple agent ITCC European Proof-of-
Concept Therapeutic Stratification Trial of Molecular Anomalies in Relapsed or Refractory Tumours 
(ESMART) study (NCT02813135).  In this study, ten patients are recruited at the RP2D including those 
in the dose confirmation study.  If there is no response in the first ten patients, then a further 
evaluation of the drug is postponed or abandoned.  However, if there is a response in the first ten 
patients, then a further 16 patients are enrolled with one interim analysis and an early stopping rule. 
The two main advantages of the 3-stage design are that: (i) the 10 patients treated at the RP2D in 
the dose confirmation (or possibly dose escalation) stage can be evaluated for response and 
correspond to the first step of the Ensign 3-stage design; therefore this design is driven by statistical 




and clinical hypotheses in the decision to move from the dose-confirmation/escalation phase to the 
expansion cohort; (ii) given the relatively low accrual of paediatric studies, a 3-stage design allows 
for a more frequent examination of the data and hence the possibility of more rapidly stopping a 
trial of an inefficient drug.  Alternative designs, including Bayesian approaches, are possible as long 
as they provide reliable data at the end of the trial for starting comparative, practice-changing trials 
(Figure 1). 
 
For agents targeting specific oncogenic drivers present in the patients’ tumours (e.g., BRAF inhibitors 
for BRAF mutated gliomas or ALK in anaplastic large cell lymphoma [ALCL]) where a predictive 
biomarker is well defined, a small, enriched expansion cohort will be sufficient to show whether the 
drug is active in terms of response rate.  In contrast, for inhibitors of cell signalling pathways (e.g., 
MEK or phosphoinositide-3 kinase (PI3K) inhibitors in unselected populations), where a predictive 
biomarker has not been well defined, expansion cohorts might not be sufficient to show single agent 
activity.  Activity signals may require a combination study and single agent studies may only 
document inhibition of a pharmacodynamic target in a homogeneous cohort of patients treated at 
the same dose allowing the drug to progress to a combination study.  In the absence of a very strong 
biomarker and resistance to monotherapies, combinations have to be explored as early as possible 
to prevent recruiting numbers of patients to single-agent expansion cohorts with a low probability of 
activity; this approach is being adopted in new trials46,47.  The potential activity of the drug as a single 
agent depends on the drug’s mechanism of action.  There are some drugs where activity can be 
expected as a single agent, e.g., targeting a strong oncogenic driver such as BRAF or ALK, but others 
where a combination study is required. It is not possible to generalise, but it is important not to 
disregard a drug as a single agent where activity might only be expected in combination with 
another.  The combination of expansion cohorts with a dose confirmation study makes the trials 
similar to phase I/II trials and we propose these should be termed “early phase clinical trials” (Figure 
1, Table 4).  An early phase trial has two principle components: i) a dose confirmation or escalation 
phase in which the toxicity profile and the RP2D and preliminary pharmacokinetics are determined, 
and ii) expansion cohorts where additional pharmacokinetic, pharmacodynamic and safety data, and 
importantly early signals of anti-tumour activity, are obtained. 
 
Later phases of development 
Success or failure criteria in single arm phase II trials, with a target of a clinically acceptable response 
rate that would lead to further evaluation of the drug, are always estimations based on historical 




data, which often underestimate the true effect of standard treatment48; hence, randomised phase II 
trials are preferred.   
 
Given the rarity of paediatric cancers, novel designs (e.g., Bayesian or a two-stage Minimax Jung 
designs) can be used to minimise sample size, which can be in the region of 25-35 patients49,50.  
Randomised phase II trials are feasible designs to evaluate new drugs in the first relapse setting for 
most poor prognosis paediatric cancers where outcome at first relapse is poor and new drugs are 
needed.  For example, currently there are three ongoing randomised clinical trials, including 
between 74 to 160 patients, evaluating targeted agents for neuroblastoma across the globe.  The 
International Society of Paediatric Oncology Europe Neuroblastoma Group (SIOPEN)/ITCC BEACON-
Neuroblastoma trial is testing three randomised questions (activity of two chemotherapy regimens 
and role of the anti-VEGF monoclonal antibody bevacizumab), which will allow evidence-based 
decisions51.  Also COG ANBL1221, a randomized phase II selection design, compared the addition of 
temsirolimus or dinutuximab plus granulocyte-monocyte colony stimulating factor to an 
irinotecan/temozolomide backbone in patients with relapsed or refractory neuroblastoma50 and 
made a conclusion with 35 randomised patients.  In a GPOH study, the addition of rapaymcin and 
dasatinib to irinotecan/ temozolomide is being compared in a randomised phase II trial52.  Similar 
platforms are being developed both sides of the Atlantic for other common tumour types such as 
Ewing sarcoma53 or rhabdomyosarcoma54.  For rarer tumour types or those with better outcome, 
such as acute lymphoblastic leukaemia or Wilms tumour, achieving the required patient numbers 
poses challenges and supports the need for global studies.  Even small, randomised trials provide 
better evidence than single arm trials49.  The major advantage of a randomised phase II trial is that it 
provides more solid evidence of activity compared to single arm trials in which the estimations for 
considering an agent successful/unsuccessful are based on historical controls. Hence, using 
randomised phase II trials will eventually result in fewer patients being needed to decide if a drug 
should or should not be advanced to a phase III trial.  Essentially, only if initial signals of activity are 
demonstrated in either a single agent or combination in an expansion cohort of an early phase 
clinical trial, will that single agent or combination be taken forward to randomised phase II trials.  
We propose new roles for early phase clinical trials, which would better inform the selection of 
agents for randomised phase II trials.  If a sufficient level of activity is confirmed in a randomised 
phase II trial, the drug should be taken forward to front-line phase III trials.  With this approach 








The Pharmacological Audit Trail in paediatric cancers 
The Pharmacological Audit Trail is a paradigm applied in adult drug development which is being 
embraced in paediatric early phase studies, including the ITCC ESMART study.  This approach, 
incorporating biological hypotheses into early clinical trials includes a continuous bench-to-bedside 
and back again strategy with predictive and pharmacodynamic biomarkers, and will accelerate and 
improve drug development55.  In parallel, pharmacogenetic studies that explore individual variability 
of new drug metabolism should be incorporated to paediatric trials.  
 
It is critical that biomarkers56 are considered in paediatric early phase clinical trials and that 
predictive and pharmacodynamic data obtained in trials in adults are applied if relevant in children.  
Table 4 describes the roles, advantages and disadvantages of types of biomarkers.  
 
Examples of the successful application of the Pharmacological Audit Trail in early phase clinical trials 
include the COG phase I trial of the AKT inhibitor MK2206, where proof of target inhibition 
biomarkers [pAkt] demonstrated effective target inhibition at the RP2D57.  The phase I trial of the 
aurora kinase inhibitor AT9283 used paired skin punch biopsies to demonstrate aurora kinase 
inhibition at higher dose levels58.  In some instances, new biomarker assays relevant to the biology of 
paediatric tumours will have to be developed and validated in studies in children, for example, for 
drugs against paediatric-specific targets such as MYCN59.  Liquid biopsies provide an opportunity to 
carry out pharmacodynamic studies sequentially in children without tumour biopsies. Also, 
paediatric studies have used functional imaging as a non-invasive biomarker to avoid repeat tumour 
biopsies; for example, dynamic contrast-enhanced magnetic resonance imaging in the study of 
pazopanib60 and tumour perfusion assessed by magnetic resonance imaging in the study of 
vandetanib61.  Extrapolation from adult, post-treatment pharmacodynamic data (with confirmation 
of comparable pharmacokinetics in adults and children) should be considered. 
 
When a predictive or pharmacodynamic biomarker for a targeted agent has not yet been found to 
correlate with the drug’s activity, exploration of this relationship could continue during later stages 
of the drug’s development.  Similarly, a biomarker that has been identified as an exploratory 
endpoint of an early phase trial should be confirmed in later stages of development. 
 
Genomic studies of tumour 
Availability of tumour material at the time of enrolment in an early phase trial will enable the 
maximal knowledge to be obtained from the study.  Although relevant for some characterisations, 




tumour from an earlier presentation is typically inappropriate, as it is well documented that clonal 
evolution occurs in the vast majority of cases62-64; in addition tumour heterogeneity also has to be 
considered.  The use of liquid biopsies, e.g., circulating free DNA65, which are collected sequentially 
during an early phase trial, is a promising approach being applied in paediatric cancers.  ITCC and 
other initiatives are now in place to routinely molecularly profile tumours at relapse (MOlecular 
Screening for CAncer Treatment Optimization [MOSCATO-01]66, Proof-of-Concept Study To Stratify 
Targeted Therapies Adapted To Molecular Profiling [MAPPYACTS], Individualized Therapy for 
Relapsed Malignancies in Childhood [INFORM]67, Individualised Therapy [iTHER], Stratified Medicine 
– Paediatrics [SM-PAEDS], NCI-COG Pedi-MATCH68, iCAT69).   As well as generating hypotheses 
regarding the evolution of the tumour and tumour heterogeneity, these protocols will determine if 
actionable mutations are present at relapse, thereby identifying potential molecularly targeted 
drugs that could be utilised in a stratified, precision medicine strategy with molecular enrichment 
and predictive biomarkers.  However, the need for tumour sampling immediately prior to study 
entry needs to be placed within the context of the agent being studied, the objectives of the clinical 
trial, the ethical justifications for tumour sampling, and the clinical status of the patient population 
being studied. 
 
Infants and very young children (<2 years of age) 
It is known that renal and hepatic functions are significantly different in children younger than 3 
years of age70 and drug metabolism and pharmacokinetic profiles can differ significantly in younger 
cohorts.  Thus collection of pharmacokinetic data in younger children is required, particularly for 
those agents focussing on malignancies occurring at younger ages, such as rhabdoid tumours or 
infant leukaemias.  However, since relapsed cancers are rare in this population, a pre-specified 
number of infants should not be pre-defined in the early phase trial protocol.  Pharmacokinetic data 
in infants should be collected also during the expansion cohort or subsequent studies.  Hence, trials 
of anticancer agents should not be stratified in age cohorts.  
 
Adolescents 
Although not based on medical or biological grounds, the upper age for “paediatric” early phase 
clinical trials is often below 18 years, which is also the lower age for many adult phase I studies.  
While it is understandable that there is a distinction between paediatric and adult populations, 
studies should be adapted to the population of interest.  Hence, a first-in-child early phase study 
with the objective of defining a “paediatric” dose and pharmacokinetic profile should concentrate on 
children and adolescents.  However, this 18-years “boundary” should not limit the access of 




adolescents (12-17 years old, according to the International Conference on Harmonization [ICH] E11) 
to early trials of new anti-cancer agents of interest.  
 
The pharmacokinetic, pharmacodynamic and toxicity profiles of drugs are very likely to be similar in 
adolescents to the adult population71.  In cases with a significant biological rationale or conditions 
that overlap between adolescents and young adults, such as Ewing sarcoma, Hodgkin lymphoma, 
high-grade glioma, soft tissue sarcoma and osteosarcoma, adolescents have been allowed in adult 
phase I studies.  This is a valid means to accelerate drug development for this population while at 
the same time ensuring that the population of interest is well represented.  For example, 
adolescents older than 12 years with Ewing or other sarcomas were included36 in phase I trials of 
anti-IGF-1R monoclonal antibodies and trials of the mTOR/DNA-PK inhibitor CC-115 included an 
expansion cohort with Ewing sarcoma including adolescents72, as did studies in melanoma73 and ALK-
positive diseases (CREATE)74.  Building on this approach, it is proposed that where the MoA of the 
drug is relevant, adolescent patients should be included in “adult” phase I trials after the dose 
escalation phase is completed and this should complement paediatric evaluation.  We propose that 
adolescents can still be included in paediatric phase-I, II and III trials to provide additional 
therapeutic opportunities and young adult patients can participate in paediatric phase II and III trials, 
especially when their diagnosis is of a more paediatric type cancer (e.g., medulloblastoma). 
 
Some adult cancers are rare in the paediatric population and occur infrequently in adolescents (e.g., 
metastatic melanoma or thyroid cancer).  When a drug developed for the adult condition is to be 
evaluated in children and adolescent patients with the same condition possibly at the same time 
point as in adults, the objective is to demonstrate that the drug has similar toxicity, 
pharmacokinetics and pharmacodynamic profiles in children and adolescents compared to adults 
and hence, a dose confirmation, not a dose escalation study, is required.  Pharmacokinetic modelling 
is a useful tool to improve and reduce the required sample size.  
 
In many instances, an adult condition might be rare in children and adolescents but the drug might 
be relevant for other paediatric cancers.  A MoA, drug development approach focusing not on 
diseases, but on targets present in different diseases with a higher frequency in children, would 
overcome these challenges20.  Together these strategies would facilitate access to new drugs and 
provide more options for adolescent patients. 
 
 




Late toxicities and long-term follow up 
Concerns about late toxicities in children, affecting areas such as growth, development or 
neurocognition, might arise with new molecularly targeted agents and these cannot be 
appropriately addressed in first-in-child studies.  However, toxicity data beyond the first cycle and in 
surviving patients should still be collected.  In cases with specific concerns, appropriate monitoring 
(e.g., bone age, growth plate or dental studies) should be implemented when relevant.  For example, 
several anti-angiogenic agents have been evaluated in paediatric patients, but only with specific 
VEGF/VEGFR blocking agents (sunitinib or pazopanib) were alterations of the growth plate described 
during the phase I trial.  As a result, to provide further insight, increased monitoring for bone and 
musculoskeletal growth has been incorporated into ongoing phase II trials for bevacizumab and 
pazopanib.  The true long-term impact of these changes will however only be evaluated when these 
agents have advanced to front-line studies and when larger populations, including long-term 
survivors, are available for evaluation.  A further example occurred with sonic hedgehog inhibitors 
vismodegib and sonidegib, which were shown to cause irreversible closure of growth plates76 in 
animal models, however first-in-child trials have not confirmed this77,78 and data from phase II trials 
are awaited79.  Finally, long-term growth delay has been reported after the chronic use of the 
tyrosine kinase inhibitor imatinib80.  Such toxicities can only be identified after long-term 
surveillance and possibly prolonged use of the drugs, and therefore, will not be easily identified 
during early clinical trials but during late trials or the post-marketing authorisation phase.  Early 
clinical trials must take into account anticipated life expectancy and consider the balance between 
incorporating rigorous assessments to detect emerging toxicities and being too burdensome for 
study participants.   
 
The long-term tolerance of new drugs assumes an even greater importance in children when cancer 
becomes a more chronic disease (CML is the prime example) and growth retardation has been 
reported with some BCR-ABL tyrosine kinase inhibitors; this could influence which drug to use within 
the same class of inhibitors81.  Similarly late sequelae are of great relevance in new drugs for a good 
prognosis malignancy, e.g., BRAF or MEK inhibitors for low grade gliomas, where efficient second 
line chemotherapy regimens with known late effects are available, but new drugs are needed. 
 
Collaboration with survivorship programmes, for example Pan Care (Pan-European Network for the 
Care of Survivors after Childhood and Adolescent Cancer), provides an optimal approach82.  A 
Working Group of ACCELERATE, the Paediatric Oncology Platform10, is implementing long-term 
follow up measures for children and adolescents receiving new anti-cancer drugs. 






The landscape in which drug development for paediatric cancers takes place has changed 
significantly over the last 15 years.  Methodological aspects of new drug development must adapt to 
this new landscape, providing more efficient results and best answers to specific ethical issues83.  
Molecularly targeted agents and immunotherapeutics require a new paradigm of drug development 
with selection of drugs based on MoA and tumour biology20.  In parallel to this approach in selecting 
new agents, drugs should be evaluated in early phase clinical trials with dose confirmation studies at 
the adult RP2D adjusted for BSA with expansion cohorts that integrate activity and biomarker 
endpoints to address biological hypotheses.  In many instances the aim is to validate the use of the 
adult dose in paediatrics, therefore extrapolation of data from adult studies should be undertaken at 
every opportunity.  If the drug has specific, serious, dose-related toxicities or a narrow therapeutic 
index, then dose escalation studies should be undertaken starting at 80% of the adult RP2D but 
increasing the trial efficiency by using new dose escalation models such as CRM or BLRM.  Expansion 
cohorts can give preliminary signals of activity determining which drugs should be evaluated further 
in randomised multi-arm or umbrella matrix studies.  By these means drugs can move from first-in-
child to front-line trials in just three steps.  Very importantly as therapeutic intent is key to the 
design of early phase studies in children, these recommendations maintain safety and activity as 
objectives, while minimising the use of protracted phase I trials.  The probability of overdosing or 
under-dosing will be reduced with increased chances that patients are treated at optimum 
therapeutic doses.  This approach is ethically desirable when evaluating drugs in children for which 
an active dose has already been established in adults and is being applied in ESMART.  
 
 Many recently developed adult cancer agents do not target childhood cancers because the genetic 
and epigenetic repertoire of driver mutations in specific childhood malignancies differs from more 
common adult-type malignancies. Therefore, there is currently a paucity of targeted cancer drugs 
addressing paediatric cancer oncogenic drivers. Developing drugs to target driver mutations in 
childhood malignancies is another key challenge of successfully applying precision medicine 
principles in paediatric oncology.   
 
A MoA model of drug development alongside innovatively and rationally designed early phase 
studies will radically accelerate development of anti-cancer drugs for children and adolescents. 
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Figure and Table Captions 
Figure 1: Schema of proposed design of early phase clinical trial in children controlling for toxicity 
and testing whether activity is above 30% and not below 10% in three-stage (Ensign) designs. 
a) Molecularly targeted drug / immunotherapeutic without serious, dose-related toxicities 
and a wide therapeutic index 
b) Molecularly targeted drug / immunotherapeutic with serious, dose-related toxicities 
and a narrow therapeutic index 
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Metric Median Range 
Age at enrolment (years) 10 1-30 
Dose levels in escalation 
cohort 
3 1-10 
Number of patients enrolled in 
escalation cohort 
18 2-67 
Number of patients enrolled in 
study 
24 6-79 
Median duration of the 92 
trials (including escalation part 





Median duration of the 54 




Table 1- Review of 92 published paediatric dose finding clinical trials in oncology and haematology 


















Definition of early phase clinical trial 
 
 
An early phase clinical trial has two principal components, i) a dose confirmation or escalation 
confirmation phase in which the toxicity profile, the RP2D and preliminary pharmacokinetics are 
determined ii) expansion cohorts where additional pharmacokinetic, pharmacodynamic and safety 
data are obtained and importantly early signals of anti-tumour activity.  “Early phase clinical trial” is 
a term that encompasses the first stages of the clinical development of a drug to define its dose, 
toxicity profile, biomarkers, and early signals of anti-tumour activity before transitioning to “late 
stage” phase II or III trials aimed at determining the drug’s efficacy.  
 
Text box 1: Definition of early phase clinical trial 
 
  




Precision medicine in children and adolescents 
 Precision medicine can be defined as therapeutic decisions guided by the molecular or genomic 
features of a tumour rather than on the basis of clinicopathological features.  
 Central to precision medicine is understanding the molecular pathways, biology and key drivers 
of paediatric malignancies, focussing on aberrations that demonstrate a proof of “tumour 
dependence”. 
 Recent sequencing has shown that the genetic and epigenetic repertoire of driver mutations in 
specific childhood malignancies differs from more common adult-type malignancies.  
 The number of non-synonymous coding mutations in childhood tumours is on average about a 
hundred-fold lower than in adult malignancies. 
 Information on the presence of actionable target mutations is the most easily obtained data; 
determination of the functional relevance of identified targets for tumour cell survival and the 
relevance of complicated tumour-host interactions is a more challenging task.  
 Currently, precision medicine in paediatric oncology focuses on actionable target mutations, 
particularly those for which there are available drugs developed for adult cancers (e.g., ALK or 
BRAF). Initial investigations suggest that these can be detected in about 50% of tumours66-69. 
 The major challenges currently in implementing precision medicine in paediatric oncology are 
that the focus is only on actionable mutations, the presence of multiple alterations and the 
limited access to targeted agents. 
 As the driver mutations in childhood malignancies differ from more common adult-type 
malignancies, many recently developed adult cancer agents do not target childhood cancers.  
Therefore, there is a paucity of targeted cancer drugs addressing paediatric cancer oncogenic 
drivers.  Developing drugs to target genomic alterations in childhood malignancies is a key 
challenge to successfully applying precision medicine principles. 
 The multiple agent ITCC European Proof-of-Concept Therapeutic Stratification Trial of Molecular 
Anomalies in Relapsed or Refractory Tumours (ESMART) study (NCT02813135) is not 100% 
enriched and restricted to patients with pre-defined molecular alterations. On the contrary, a 
secondary objective is to compare outcomes of patients with molecular abnormalities, matching 
the treatment to those without druggable targets.  
 Although significant progress has been made, drug development for children with cancer is still 
focused on adult conditions. A recent analysis suggests that 73% of new anti-cancer agents, 
whose evaluation in children was waivered, had a target or MoA that would warrant paediatric 
development based on existing molecular data. 




 We propose that prioritisation of targeted agents is facilitated by Paediatric Strategy Forums.  
The output of a Paediatric Strategy Forum would provide a perspective that that will enable all 
stakeholders to have an overview of the landscape, which will facilitate sharing of information 
and advance learning, which will help inform subsequent decisions. 
 In a Mechanism of Action approach to development of drugs for children and adolescents with 
cancer, all hallmarks of cancer including epigenetics and immunotherapy are targeted. 
 
Text box 2: Precision medicine in children and adolescents 
  




Ethical aspects related to paediatric oncology early phase clinical trials83 
 
 Ethics should guide all aspects of early phase clinical trials within the legal framework25.  
Specific aspects related to paediatric early phase clinical trials are: 
 Therapeutic intent 
 Ancillary studies and invasive biopsies 
 Consent/Assent 
 Minimisation of all risks and distress to the patient 
 The scientific information gained from an early phase clinical trial must be weighed against 
ethical aspects. 
 Ethical issues can be broadly grouped into four areas: research ethics, legal and ethical 
consistency, professionalism and consent. 
 That the research objectives and underlying scientific rationale of the research is strong is of 
pivotal importance. 
 Therapeutic intent is central to early phase clinical trials in paediatric malignancy. 
 An early phase clinical trial is an option to be proposed to the patient and his / her parents.  
 Availability of tumour material at the time of enrolment in an early phase trial will enable 
the maximal knowledge to be obtained from the study. Generally, using archival tumour 
from an earlier presentation is inappropriate, as it is well documented that clonal evolution 
occurs in the vast majority of cases.  Data from a tumour biopsy could identify potential 
molecularly targeted drugs that could be utilised in a precision medicine strategy with 
molecular enrichment and predictive biomarkers. The need for tumour sampling 
immediately prior to study entry needs to be placed within the context of the agent being 
studied, the objectives of the clinical trial, the ethical justifications for tumour sampling, the 
accessibility of tumour material and the clinical status of the individual patient.  
 The inclusion of ancillary/biological studies (tumour analysis and pharmacodynamic studies) 
increases the scientific value of early phase clinical trials, and thus, the future use of the 
drug. For instance, to understand issues such as genetic variability of drug metabolism or 
mechanisms of drug resistance are central questions, which should be studied as early as 
possible during a drug’s development.  
 Much information regarding pharmacodynamic biomarkers can be obtained non-invasively 
or by blood sampling. We believe that a way forward should be developed so that early drug 
development can be efficient and based on scientific information through pharmacodynamic 
and biological studies whilst abiding by ethical constraints. 




 Liquid biopsies have an important potential future role as they may provide relevant 
molecular diagnostic, prognostic, predictive information and might be used during 
treatment to predict response / resistance to treatment with minimal distress to the 
patients. 
 Starting to evaluate drugs in the paediatric population at doses substantially below those 
already established to be active in adults raises ethical concerns, as therapeutic intent is 
central to studies in children. An equivalent dose of the minimum active target exposure 
should be mandatory for the paediatric starting dose for most agents. 
 All care should be taken during the design of a new protocol to minimize distress to patients, 
including: the number of hospital visits, uncomfortable tests, frequent sedations, painful 
procedures and the number of diagnostic procedures. 
 
Text box 3: Ethical aspects related to paediatric oncology early phase clinical trials  
 
